DR Corporation Limited (SHE:301177)

Achilles Therapeutics Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	158.93	139.79	227.85	521.9	4,742	181.5
Short-Term Investments	-	518.71	475.88	97.46	161.63	-
Trading Asset Securities	4,803	4,579	4,842	5,610	1,824	921.53
Cash & Short-Term Investments	4,962	5,238	5,546	6,229	6,727	1,103
Cash Growth	-4.67%	-5.55%	-10.97%	-7.40%	509.89%	118.41%
Accounts Receivable	74.11	80.91	83.15	84.48	174.88	166.19
Other Receivables	6.01	9.71	36.72	23.31	13.09	0.76
Receivables	80.13	90.62	119.87	107.79	187.98	167.99
Inventory	456.19	447.45	526.94	669.89	439.97	297.13
Other Current Assets	981.71	104.93	106.32	142.06	95.7	50.7
Total Current Assets	6,480	5,881	6,299	7,149	7,451	1,619
Property, Plant & Equipment	134.22	160.63	221.59	604.57	435.62	3.28
Long-Term Investments	428.92	973.56	891.98	794.55	218.59	156.01
Other Intangible Assets	464.67	468.81	6.61	4.26	5.88	6.32
Long-Term Deferred Tax Assets	11.69	12.6	15.29	8.19	4.77	5.03
Long-Term Deferred Charges	29.07	-	-	-	-	73.66
Other Long-Term Assets	22.56	55.88	95.8	254.82	152	66.97
Total Assets	7,571	7,552	7,530	8,816	8,269	1,932
Accounts Payable	71.68	64.18	76.15	553.41	455.45	308.15
Accrued Expenses	30	90.1	93.26	126.4	189.32	100.32
Short-Term Debt	360.44	339.51	390	433.99	-	-
Current Portion of Leases	95.67	118.68	195.52	351.52	215.04	-
Current Income Taxes Payable	30.33	9.16	0.3	34.16	72.02	59.41
Current Unearned Revenue	103.73	112.69	109.63	126.71	210.15	253.51
Other Current Liabilities	470.28	421.08	96.06	84.29	27.97	82.59
Total Current Liabilities	1,162	1,155	960.92	1,710	1,170	803.98
Long-Term Leases	47.21	57.72	67.78	276.54	215.67	-
Long-Term Deferred Tax Liabilities	12.69	13.27	14.64	8.75	4.61	0.57
Other Long-Term Liabilities	3.17	2.4	14.1	16.93	12.39	8.69
Total Liabilities	1,225	1,229	1,057	2,013	1,403	813.23
Common Stock	400.01	400.01	400.01	400.01	400.01	360
Additional Paid-In Capital	4,460	4,404	4,404	4,404	4,404	51.33
Retained Earnings	1,482	1,461	1,608	1,939	2,010	708.27
Comprehensive Income & Other	3.31	58.46	60.62	59.98	52.73	-1.25
Total Common Equity	6,346	6,324	6,473	6,803	6,867	1,118
Minority Interest	-	-	-	-	-	0.05
Shareholders' Equity	6,346	6,324	6,473	6,803	6,867	1,118
Total Liabilities & Equity	7,571	7,552	7,530	8,816	8,269	1,932
Total Debt	503.32	515.91	653.29	1,062	430.71	-
Net Cash (Debt)	4,458	4,722	4,892	5,167	6,297	1,103
Net Cash Growth	-6.11%	-3.48%	-5.32%	-17.94%	470.84%	118.41%
Net Cash Per Share	10.97	11.58	12.06	12.90	17.51	3.05
Filing Date Shares Outstanding	400.01	400.01	400.01	400.01	400.01	360
Total Common Shares Outstanding	400.01	400.01	400.01	400.01	400.01	360
Working Capital	5,318	4,725	5,338	5,439	6,281	814.86
Book Value Per Share	15.86	15.81	16.18	17.01	17.17	3.11
Tangible Book Value	5,881	5,855	6,466	6,799	6,861	1,112
Tangible Book Value Per Share	14.70	14.64	16.16	17.00	17.15	3.09
Machinery	-	30.46	28.66	24.39	13.62	9.16

Source: S&P Global Market Intelligence. Standard template. Financial Sources.